Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

European Medicines Agency acknowledges limitations of paediatric licensing rules

The European Medicines Agency has acknowledged that there is a lack of development of medicines for paediatric cancers after the Institute for Cancer Research claimed that children with cancer are missing out on new medicines because of EU rules.

In a statement issued earlier this week (10 February 2014), the ICR explained that currently medicines for adult diseases are only required to be tested in the paediatric population if the same disease also affects children. It points out that many cancer medicines licensed for adults are exempt even though there are childhood cancers with common genetic features. To illustrate the point, the ICR says that out of the 28 cancer medicines that have gained EU approval since 2007, 26 have a mechanism of action that suggests they could be effective in childhood cancers. However, 14 of these have had the requirement for paediatric testing waived.

In response to the claims, the EMA — which is responsible for evaluating medicines put forward for an EU licence — conceded that there is a lack of development of childhood cancer medicines. “[The EMA] is working actively with its partners across the EU to address this unmet medical need,” said a spokeswoman. She explained that the EU Paediatric Regulation was designed to increase the number of medicines for children and she claimed that overall this Regulation has been a success. However, she added that the Regulation does not give regulatory authorities the legal right to compel companies to develop a particular medicine for a different condition from the adult one.

But the ICR, in partnership with the European Consortium for Innovative Therapies for Children with Cancer (ITCC), is calling for the EU to scrap the current system of waivers and exemptions. “Specifically, the ICR wants the European Commission to refuse to grant waivers to pharmaceutical companies exempting them from testing cancer drugs in children on the basis that the adult cancer targeted does not occur in children.”

The EMA spokeswoman said that the lack of availability of medicines for paediatric cancers has been highlighted in the European Commission’s five-year progress report on the impact of the EU Paediatric Regulation and identified as an area for future work.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.11134267

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Child receiving intravenous therapy (Pleprakaymas/Dreamstime.com)

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.